Skip to main content
. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980

Figure 1.

Figure 1.

Kinome profiling of acalabrutinib, ibrutinib, and zanubrutinib at a single dose of 1 mM (KINOMEscan; Eurofins DiscoverX, Fremont, CA).

Source: Adapted with permission from Kaptein et al. 45